Lineage Cell Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $6,608 | $3,681 | $2,765 | $1,502 |
Gross Profit | 5,843 | 3,676 | 2,726 | 1,466 |
EBITDA | -6,362 | -29,574 | -4,769 | -6,341 |
EBIT | -6,548 | -29,752 | -4,940 | -6,505 |
Net Income | 851 | -29,781 | -30,464 | -4,139 |
Net Change In Cash | 6,608 | 3,681 | 2,765 | 1,502 |
Free Cash Flow | -4,989 | -3,628 | -5,553 | -4,983 |
Cash | 40,791 | 40,463 | 42,271 | 47,886 |
Basic Shares | 230,116 | 228,853 | 228,356 | 226,054 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $14,556 | $9,499 | $8,945 | $14,703 |
Gross Profit | 13,711 | 9,165 | 8,274 | 13,975 |
EBITDA | -21,080 | -20,869 | -24,041 | -21,793 |
EBIT | -21,779 | -21,478 | -24,733 | -22,520 |
Net Income | -63,533 | -18,609 | -21,486 | -26,273 |
Net Change In Cash | 14,556 | 9,499 | 8,945 | 14,703 |
Cost of Revenue | -43,468 | |||
Free Cash Flow | -19,441 | -23,657 | -29,240 | 646 |
Cash | 40,791 | 45,789 | 35,442 | 11,355 |
Basic Shares | 230,116 | 200,193 | 172,663 | 169,792 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | $0.003 |
2025-09-30 | -$0.13 |
2025-06-30 | -$0.13 |
